Browse SLC26A11

Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Lysosome membrane; Multi-pass membrane protein
Domain PF01740 STAS domain
PF00916 Sulfate permease family
Function

Exhibits sodium-independent sulfate anion transporter activity that may cooperate with SLC26A2 to mediate DIDS-sensitive sulfate uptake into high endothelial venules endothelial cells (HEVEC).

> Gene Ontology
 
Biological Process GO:0006820 anion transport
GO:0006821 chloride transport
GO:0006835 dicarboxylic acid transport
GO:0006885 regulation of pH
GO:0008272 sulfate transport
GO:0015698 inorganic anion transport
GO:0015701 bicarbonate transport
GO:0015711 organic anion transport
GO:0019532 oxalate transport
GO:0030004 cellular monovalent inorganic cation homeostasis
GO:0030641 regulation of cellular pH
GO:0042391 regulation of membrane potential
GO:0046942 carboxylic acid transport
GO:0051453 regulation of intracellular pH
GO:0055067 monovalent inorganic cation homeostasis
GO:0072348 sulfur compound transport
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1902358 sulfate transmembrane transport
GO:1902476 chloride transmembrane transport
Molecular Function GO:0005216 ion channel activity
GO:0005253 anion channel activity
GO:0005254 chloride channel activity
GO:0008271 secondary active sulfate transmembrane transporter activity
GO:0008509 anion transmembrane transporter activity
GO:0008514 organic anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015106 bicarbonate transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015116 sulfate transmembrane transporter activity
GO:0015267 channel activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015297 antiporter activity
GO:0015301 anion:anion antiporter activity
GO:0019531 oxalate transmembrane transporter activity
GO:0022803 passive transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0099516 ion antiporter activity
GO:1901682 sulfur compound transmembrane transporter activity
Cellular Component GO:0005765 lysosomal membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-427601: Multifunctional anion exchangers
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC26A11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC26A11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC26A11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1460.617
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3140.836
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.480.675
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4520.333
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4020.83
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5180.833
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0880.798
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.030.98
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1740.897
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9170.414
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4840.342
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0150.854
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC26A11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC26A11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC26A11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC26A11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC26A11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC26A11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC26A11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC26A11
Namesolute carrier family 26 (anion exchanger), member 11
Aliases solute carrier family 26, member 11; Solute carrier family 26 member 11; Sodium-independent sulfate anion tr ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC26A11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.